Pharmaceutical giant Eli Lilly has suspended clinical trials of its monoclonal antibody drug. (Photo: Internet)
Indianapolis, October 14 (RHC)-- Pharmaceutical giant Eli Lilly has suspended clinical trials of its monoclonal antibody drug over an unspecified “potential safety concern.”
President Donald Trump touted a similar drug produced by Regeneron as a “cure” for COVID-19 after he received a dose while hospitalized at Walter Reed Medical Center earlier this month.
Both Eli Lilly and Regeneron have applied for emergency use authorizations of their antibody therapies.
